How do you introduce a Swiss biotech with an emerging clinical pipeline in a crowded oncology space to U.S. investors while still demonstrating value with the current catalyst and value drivers? SmithSolve defined its corporate story, branded its image and raised its corporate visibility.


  • Introduce, explain DARPin® technology platform to highlight its value, potential and future opps.
  • Show clinical, commercial potential of abicipar and upcoming DARPin® compounds
  • Highlight emerging pipeline in oncology and demonstrate potential even at an early stage
  • Differentiate and better communicate the DARPin® technology to all key stakeholders
  • Build investor confidence in pipeline and help attract capital



  • Worked with management team to structure event flow by anticipating areas of high interest
  • Provided feedback to presentation to highlight new data to show potential of platform and to ensure it was presented in a clear, understandable and consistent way
  • Coordinated KOL participation to provide credibility to disease states
  • Developed materials to introduce new technology, including: boilerplate, core messages document, and revised website copy to ensure consistency across platforms
  • Developed Q&A to guide management team through tough questions


  • Attracted 52 investors in-person
  • Secured 35 participants via webcast
  • Consistent corporate materials along with corporate branding
  • Secured positive feedback from post-event survey regarding event flow, content, value

“A very warm welcome from my side. It’s a great pleasure to be here in New York for the first ever R&D Day of Molecular Partners. I’m very happy and grateful to be here and showcase our pipeline — we’re opening a new chapter for our company.” – Patrick Amstutz, chief executive officer of Molecular Partners